Abstract: A system and method are provided for secure network communications. A proxy server receives meter data, from a meter of a set of meters via a local network, for an energy management server. The proxy server uses secure communications to send the meter data via a non-secure network to the energy management server.

Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Abstract: An engine cranking system and a method of cranking an engine are provided. The engine cranking system comprises an engine, cranking motor, and capacitor. The engine cranking system further comprises an electrical path interconnecting the cranking motor or a battery to the capacitor. The engine cranking system further comprises a control circuit coupled to the capacitor. The control circuit comprises a timer operative to track temporal information. The control circuit is operative to apply a control voltage that varies in response to the tracked temporal information. The control circuit further comprises a relay included in the electrical path. The relay is operative to switch, in response to the control voltage, between an open-circuit condition, in which the relay interrupts the electrical path, and a closed-circuit condition.

Abstract: Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.

Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

Abstract: Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Abstract: An extendible axle member (146 or 148) is provided for a pivoting axle of an agricultural harvester (100), the extendible axle member (146 or 148) having an elongate telescopic portion (400) with bearing surfaces for being slidably received in an outer axle member (142 or 144), wherein the elongate telescopic portion (400) is formed integral with and abuts a C-frame for supporting a steering knuckle (158 or 160).

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: An engine cranking system and a method of cranking an engine are provided. The engine cranking system comprises an engine, cranking motor, and capacitor. The engine cranking system further comprises an electrical path interconnecting the cranking motor or a battery to the capacitor. The engine cranking system further comprises a control circuit coupled to the capacitor. The control circuit comprises a timer operative to track temporal information. The control circuit is operative to apply a control voltage that varies in response to the tracked temporal information. The control circuit further comprises a relay included in the electrical path. The relay is operative to switch, in response to the control voltage, between an open-circuit condition, in which the relay interrupts the electrical path, and a closed-circuit condition.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Abstract: A system provides an intra-program event guide for display. The intra-program event guide enables a User to identify the events (e.g. scenes, episodes, alternative scenes, program portions etc.) occurring within a program and to initiate viewing (or initiate other functions associated with the event) via the guide. A method for processing information concerning intra-program events (e.g. comprising particular MPEG compatible groups of pictures (GOPS)) occurring within a program involves receiving signal data and identifying in the signal data information items describing intra-program events occurring during a program. The information items describing intra-program events are processed to provide processed data representative of intra-program events sequentially ordered by time and the processed data is communicated to a device. Generation of an intra-program event guide of the information items is initiated in response to user command.

Abstract: Gadgets integrate with spreadsheets and the spreadsheet calculation engine. A gadget is bound to a range of cells (one or more) within a sheet. When one or more of the cells of the bound range is accessed (e.g. selected, hovered over, edited, deleted, added), the gadget is notified. The gadget may use this information for updating a display rendered by the gadget and/or performing some other action. The gadget uses an Application Programming Interface (API) to create the binding, communicate with the spreadsheet, and perform actions in the spreadsheet. The gadget is a Named Item object within the spreadsheet such that the gadget may be viewed/displayed differently from other objects. Out of date requests from the gadget are attempted to be detected and prevented from being processed such that the gadget is not acting on the latest data.

Abstract: The present application discloses a method of shaping a working material (12) into an article, consisting of two primary stages: (a) in the absence of added heat, consolidating and shaping the working material into a pre-form shape using a dynamic hydroforming process that employs a rigid, male-shaped tool (32) and a non-rigid, female-shaped tool (23, 24, 26); and (b) in the presence of added heat, further consolidating and shaping the working material into the final shape using at least one additional rigid forming tool (50).

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.